Highlight
1. Dementia develops 4- to 20-fold more frequently in individuals with severe, treatment-resistant schizophrenia than in the general population.
2. The pattern of cognitive impairment in severe schizophrenia dementia differs from Alzheimer disease (AD), frontotemporal dementia (FTD), and Lewy body dementia (LBD), resembling an intensified form of schizophrenia-related cognitive deficits.
3. Common genetic risk factors for dementia, including APOE4 and known Mendelian mutations, are significantly less prevalent or absent in this cohort.
4. Cognitive impairment is not explained by premorbid intellectual disability, pharmacotherapy, cardiometabolic risks, or institutionalization effects.
Study Background
Dementia is a profound clinical issue affecting individuals with schizophrenia, especially those with severe, treatment-resistant forms. This population faces a substantially elevated risk of developing dementia, with incidences reported to be 4- to 20-fold higher than in the general population. Despite this, the etiology of dementia in schizophrenia remains unclear, and it is uncertain whether this dementia reflects common neurodegenerative disorders such as Alzheimer disease or is a distinct clinical entity. Given the significant burden and clinical implications, characterizing the cognitive profile, clinical features, and genetic underpinnings of dementia in this subgroup is urgently needed to guide diagnosis, management, and research efforts.
Study Design
This retrospective cohort study was conducted at New York state hospitals between December 2017 and July 2019. The cohort included 155 individuals diagnosed with severe, extremely treatment-resistant schizophrenia (SETRS) according to DSM-5 criteria, with continuous hospitalization for at least 5 years. Exclusion criteria comprised forensic hospitalization, known medical causes of psychosis, and recent substance abuse, ensuring a well-defined population. Cognitive assessments were conducted using the Montreal Cognitive Assessment (MoCA). Clinical and genetic data—including APOE genotyping and screening for pathogenic variants in Mendelian dementia genes—were also collected. These data were compared to a large reference cohort from the National Alzheimer Coordinating Center dataset, including participants diagnosed with Alzheimer disease, frontotemporal dementia, Lewy body dementia, vascular dementia, and healthy controls. Data analysis utilized multiple regression models to probe the relations between demographic, clinical, and genetic factors with cognitive outcomes. Data analysis was performed from January 2025 through December 2025.
Key Findings
The study’s cohort exhibited profound cognitive impairment: 98.7% scored below the mild cognitive impairment cutoff (MoCA<26), and 47.1% scored below 10, a threshold indicative of severe dementia (mean MoCA 9.8 ± 6.4). The cognitive profile at the individual MoCA item level markedly differed from profiles seen in Alzheimer disease and frontotemporal dementia but correlated strongly (Pearson r=0.86, P<.001) with cognitive patterns observed in community-dwelling individuals with schizophrenia, suggesting an intensified form of schizophrenia-related cognitive decline rather than classic neurodegenerative dementia.
Genetically, no participant harbored pathogenic variants in known Mendelian dementia genes, a significant finding that argues against typical hereditary neurodegenerative etiologies. Notably, the frequency of the APOE4 allele, a well-established risk factor for Alzheimer disease and Lewy body dementia, was significantly reduced in the SETRS cohort (14.4%) compared to AD (33.6%; OR 0.33, 95% CI 0.20-0.53, P<.001) and LBD groups (24.7%; OR 0.51, 95% CI 0.29-0.89, P=.01), suggesting divergent genetic pathways underlying dementia in this severe schizophrenia population.
Multivariate analyses ruled out common confounders such as premorbid intellectual disability, inadequate cognitive testing effort, effects of antipsychotic or other psychotropic medications, cardiometabolic risk factors, and the consequences of prolonged institutionalization as drivers of the observed cognitive impairments. This comprehensive exclusion strengthens the argument for a unique dementia syndrome intrinsic to severe schizophrenia.
Expert Commentary
The findings challenge traditional conceptions that dementia in schizophrenia is primarily due to Alzheimer’s pathology or vascular and metabolic contributions. Dr. Theodore E. Goldberg, a co-author and expert in schizophrenia cognition, notes that, “The distinct cognitive pattern and genetic profile indicate a need to conceptualize dementia in severe schizophrenia as a separate clinical entity, possibly with unique underlying pathophysiology.” These data emphasize the urgency of developing targeted diagnostic tools and therapeutic strategies specific to this population.
Limitations of the study include its retrospective design and hospital-based cohort, which may limit generalizability to less severe cases or community settings. Additionally, the lack of longitudinal biomarker data means the neurodegenerative process cannot be definitively characterized. Future prospective studies incorporating imaging, fluid biomarkers, and postmortem neuropathology will be pivotal.
Conclusion
This investigation demonstrates that dementia in severe, extremely treatment-resistant schizophrenia constitutes a distinct clinical and genetic syndrome, divergent from common neurodegenerative dementias. The pronounced cognitive impairment mirrors and intensifies schizophrenia-related deficits but does not appear driven by typical Alzheimer’s or other dementia pathologies. Importantly, the markedly lower frequency of APOE4 and absence of Mendelian mutations indicate novel genetic factors may be implicated. These insights call for re-examining dementia diagnoses in schizophrenia and tailoring research and clinical approaches to address this unique phenotype.
Understanding this syndrome may ultimately improve prognosis and treatment options, supporting more accurate cognitive assessment, refined genetic counseling, and innovative therapeutic interventions in a population with critical unmet needs.
Funding and ClinicalTrials.gov
The study was conducted with institutional support from New York state hospitals and research grants supporting neuropsychiatric genetics and cognitive neuroscience. No specific clinical trial registration number was associated with this retrospective analysis.
References
- Pathak US, Mehralizade A, Goldberg TE, Zoghbi AW. Dementia in Severe Schizophrenia. JAMA Psychiatry. 2026 Jun 1;83(6):590-600. doi:10.1001/jamapsychiatry.2026.XXXXXX.
- Barch DM, Sheffield JM. Cognitive impairments in psychotic disorders: Common mechanisms and measurement. World Psychiatry. 2014 Oct;13(3):224-32. doi:10.1002/wps.20143.
- Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Controlled Trials. Schizophr Bull. 2015;41(4):892-899. doi:10.1093/schbul/sbu167.
- Murray ME, Cullen NC, Langmore SE, et al. Cognitive impairment in schizophrenia: A systematic review of structural and functional imaging studies. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109645. doi:10.1016/j.pnpbp.2019.109645.
